With FDA Approval and Pfizer Deal in Hand, Myovant Appoints New CEO

After guiding Myovant to a successful FDA approval and inking a $4.2 billion deal with pharma giant Pfizer, Chief Executive Officer (CEO) Lynn Seely is bowing out to make room for the next chief, David Marek.